Novel RNA Helicase Inhibitor to Treat Breast Cancer.

摘要

During the no-cost extension period, we tried to resolve the problems we were having with attempting to encapsulate NZ51 in various copolymers to facilitate faster release in mouse plasma. Even the use of PLGA or chitosan derivatives did not resolve the problems. Currently, we are postulating that the chemical structure of NZ51 is interfering with the formulation and utility for in vivo experiments. Subsequently, we attempted to encapsulate a different DDX3 inhibitor into PLGA nanoparticle. This appears to be more feasible than NZ51. The manuscript describing the formulation, release kinetics and cytotoxic effects using a different DDX3 inhibitor is in preparation. In addition, we have completed the study with NZ51 as well (in preparation), which indicated that NZ51 although very efficient in killing breast cancer cells in vitro was far less efficient in controlling tumor growth in a preclinical model of breast cancer.